{"id":4902,"date":"2020-09-19T10:09:00","date_gmt":"2020-09-19T09:09:00","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=4902"},"modified":"2021-10-11T16:26:52","modified_gmt":"2021-10-11T15:26:52","slug":"24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/","title":{"rendered":"Live webinar GARDP \/ JPIAMR: &#8220;Moving from preclinical to clinical-stage: Challenges and opportunities&#8221;, 24 Sept 2020"},"content":{"rendered":"\n<p>GARDP is organising a live webinar on the 24th of September: Moving from preclinical to clinical-stage: Challenges and opportunities.<\/p>\n\n\n\n<p>This webinar was developed by GARDP in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part of the \u2018Antibiotic Bootcamps for Developers\u2019 series which have been developed by GARDP and its partners at the \u2018ASM\/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance\u2019 since 2017. As this years\u2019 conference could not be held, the content was developed under the umbrella of the REVIVE webinar series.<\/p>\n\n\n\n<ul><li>Read more and register : <a href=\"https:\/\/gardp.org\/news-resources\/webinar-moving-from-preclinical-to-clinical-stage-challenges-opportunities\/\">https:\/\/gardp.org\/news-resources\/webinar-moving-from-preclinical-to-clinical-stage-challenges-opportunities\/<\/a><\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>GARDP is organising a live webinar on the 24th of September: Moving from preclinical to clinical-stage: Challenges and opportunities. This webinar was developed by GARDP in collaboration with CARB-X, JPIAMR, REPAIR Impact Fund, Wellcome Trust, ASM and ESCMID. It is part of the \u2018Antibiotic Bootcamps for Developers\u2019 series which have been developed by GARDP and [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[35],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Live webinar GARDP \/ JPIAMR: &quot;Moving from preclinical to clinical-stage: Challenges and opportunities&quot;, 24 Sept 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Live webinar GARDP \/ JPIAMR: &quot;Moving from preclinical to clinical-stage: Challenges and opportunities&quot;, 24 Sept 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-19T09:09:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-11T15:26:52+00:00\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Live webinar GARDP \/ JPIAMR: &#8220;Moving from preclinical to clinical-stage: Challenges and opportunities&#8221;, 24 Sept 2020\",\"datePublished\":\"2020-09-19T09:09:00+00:00\",\"dateModified\":\"2021-10-11T15:26:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\"},\"wordCount\":115,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"articleSection\":[\"Ev\u00e8nements &amp; Colloques\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\",\"name\":\"Live webinar GARDP \/ JPIAMR: \\\"Moving from preclinical to clinical-stage: Challenges and opportunities\\\", 24 Sept 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"datePublished\":\"2020-09-19T09:09:00+00:00\",\"dateModified\":\"2021-10-11T15:26:52+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ev\u00e8nements &amp; Colloques\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Live webinar GARDP \/ JPIAMR: &#8220;Moving from preclinical to clinical-stage: Challenges and opportunities&#8221;, 24 Sept 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Live webinar GARDP \/ JPIAMR: \"Moving from preclinical to clinical-stage: Challenges and opportunities\", 24 Sept 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/","og_locale":"fr_FR","og_type":"article","og_title":"Live webinar GARDP \/ JPIAMR: \"Moving from preclinical to clinical-stage: Challenges and opportunities\", 24 Sept 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2020-09-19T09:09:00+00:00","article_modified_time":"2021-10-11T15:26:52+00:00","author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Live webinar GARDP \/ JPIAMR: &#8220;Moving from preclinical to clinical-stage: Challenges and opportunities&#8221;, 24 Sept 2020","datePublished":"2020-09-19T09:09:00+00:00","dateModified":"2021-10-11T15:26:52+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/"},"wordCount":115,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"articleSection":["Ev\u00e8nements &amp; Colloques"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/","name":"Live webinar GARDP \/ JPIAMR: \"Moving from preclinical to clinical-stage: Challenges and opportunities\", 24 Sept 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"datePublished":"2020-09-19T09:09:00+00:00","dateModified":"2021-10-11T15:26:52+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/24-sept-live-webinar-gardp-jpiamr-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Ev\u00e8nements &amp; Colloques","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/"},{"@type":"ListItem","position":4,"name":"Live webinar GARDP \/ JPIAMR: &#8220;Moving from preclinical to clinical-stage: Challenges and opportunities&#8221;, 24 Sept 2020"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-14 17:17:13","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/4902"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=4902"}],"version-history":[{"count":5,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/4902\/revisions"}],"predecessor-version":[{"id":18035,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/4902\/revisions\/18035"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=4902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=4902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=4902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}